{"gao_id": "GAO-19-565", "published": "2019-08-07T12:00:00Z", "released": "2019-08-07T08:00:00Z", "summary": "Companies that make generic drugs\u2014which have the same active ingredients as brand-name drugs\u2014have to apply for FDA approval to market them. After reviewing an application, FDA may return it with comments. The company can address the comments and resubmit. On average, applications go through 3 of these review cycles before approval (which may take years). We found FDA approved 12% of generic drug applications in...", "title": "Generic Drug Applications: FDA Should Take Additional Steps to Address Factors That May Affect Approval Rates in the First Review Cycle", "topics": ["Cost savings", "Health care cost control", "Generic drugs", "Health and safety", "Prescription drugs", "Health care standards", "Drugs", "Drug safety", "New drugs", "Health Care", "Product development"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-19-565", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-19-565-highlights.pdf"}, {"title": "Full Report (38 pages)", "url": "https://www.gao.gov/assets/gao-19-565.pdf"}, {"title": "Accessible PDF (44 pages)", "url": "https://www.gao.gov/assets/710/700800.pdf"}]}